In healthcare, a paradigm shift is under way towards more patient-centred individualized treatment approaches. Personalized medicine offers the opportunity for a more effective, better tolerated and economic healthcare practice. CI3 is spearheading personalized medicine, by focusing on the use of the human immune system for the treatment of life-threatening conditions such as cancer, autoimmune diseases and infections. It is our vision to combine the outstanding scientific excellence and commercial expertise of our cluster partners in the Rhine-Main Metropolitan Region, to develop new immune intervention strategies with large economic potential and to position CI3 among the prime immunology clusters in Europe. To turn our vision into reality, CI3 has established a network of more than 120 partners from industry, research, patient care and government, along the entire innovation and value chain.